Abstract
Up to 15% of human cancers maintain their telomeres through a telomerase-independent mechanism, termed “alternative lengthening of telomeres” (ALT) that relies on homologous recombination between telomeric sequences. Emerging evidence suggests that the recombinogenic nature of ALT telomeres results from the formation of RNA:DNA hybrids (R-loops) between telomeric DNA and the long-noncoding telomeric repeat-containing RNA (TERRA). Here, we show that the mismatch repair protein MutSβ, a heterodimer of MSH2 and MSH3 subunits, is enriched at telomeres in ALT cancer cells, where it prevents the accumulation of telomeric G-quadruplex (G4) structures and R-loops. Cells depleted of MSH3 display increased incidence of R-loop-dependent telomere fragility and accumulation of telomeric C-circles. We also demonstrate that purified MutSβ recognizes and destabilizes G4 structures in vitro. These data suggest that MutSβ destabilizes G4 structures in ALT telomeres to regulate TERRA R-loops, which is a prerequisite for maintenance of telomere integrity during ALT.
Originalsprog | Engelsk |
---|---|
Artikelnummer | 110602 |
Tidsskrift | Cell Reports |
Vol/bind | 39 |
Udgave nummer | 1 |
Antal sider | 19 |
ISSN | 2211-1247 |
DOI | |
Status | Udgivet - 2022 |
Bibliografisk note
Funding Information:We wish to thank Kai Neelsen, Stanislaw Jozwiakowski, Andres Lopez Contreras, and Ian Hickson for critical reading of the manuscript and helpful discussions. In addition, we would like to thank Diana Odermatt and Kerstin Gari for their advice with G4 assays. J.P.D. was supported by the Danish Council for Independent Research ( DFF-4004-00117 ), the Danish Cancer Society ( R72-A4181-13-S2 ), the Nordea Foundation, Agnes and Poul Friis Fond, and Magda Sofie and Aase Lutz Mindelegat. P.J. was supported by the Swiss National Science Foundation ( 310030_184716 ) and Czech Science Foundation ( 19-07674S ). J.B. was supported by the Danish Council for Independent Research ( DFF-7016-00313 ), the Danish Cancer Society ( R204-A12617 ), the Novo Nordisk Foundation ( 200C0060590 ), the Czech Science Foundation (project 19-21325S ), the Swedish Research Council ( VR-MH 2014-46602-117891-30 ), and the Swedish CancerFonden ( no. 170176 ) and A.A. by the European Research Council ( ERC2014 AdG669898 TARLOOP ), the Spanish Ministry of Science and Innovation ( PID2019-104270GB-I00/BMC ), and the European Union (FEDER).
Publisher Copyright:
© 2022 The Author(s)